CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study

BACKGROUND: The role of the CYP2C19 genotype on clopidogrel efficacy has been studied widely, with data suggesting reduced clopidogrel efficacy in loss-of-function variant carriers taking clopidogrel after percutaneous coronary intervention; however, data are limited regarding the association betwee...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Am Heart Assoc
Glavni autori: McDonough, Caitrin W, McClure, Leslie A, Mitchell, Braxton D, Gong, Yan, Horenstein, Richard B, Lewis, Joshua P, Field, Thalia S, Talbert, Robert L, Benavente, Oscar R, Johnson, Julie A, Shuldiner, Alan R
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Ltd 2015
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599525/
https://ncbi.nlm.nih.gov/pubmed/26019129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.114.001652
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items